Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin86.1%+1.6pp84.5%+3.9pp80.7%+8.7pp72%-6.9pp78.8%+10.3pp
Net margin101.6%+23.4pp78.2%+36.3pp41.9%+37.6pp4.3%+231pp-226.6%+220pp
Returns
Return on equity100.7%+15.0pp85.7%+50.8pp34.8%+31.3pp3.5%+208pp-204.8%+3.1pp
Return on invested capital-0.1%+49.8pp-49.9%+3.2pp-53.2%+11.4pp-64.6%+120pp-184.7%+6.4pp
Efficiency
Asset turnover0.5×+0.1×0.5×+0.1×0.4×+0.1×0.3×+0.1×0.3×+0.1×
Liquidity
Current ratio4.9×-0.8×5.7×-2.9×8.6×+0.8×7.9×+4.8×+0.5×
Leverage
Debt-to-equity-0.4×0.4×-0.1×0.5×-0.1×0.5×-1.0×1.5×0.0×
Net debt / EBITDA-35.8×
Per Share
Book value per share$3.42+26.5%$2.70+13.5%$2.38+14.4%$2.08+174%$0.76-11.6%
Valuation
Market capitalization$773.23M+56.4%$504.43M-5.5%$533.84M+6.7%$500.32M+23.4%$405.33M-8.9%
Price / earnings6.2×6.1×-9.1×15.1×-174×189.2×
Price / sales6.3×-5.9×4.7×-1.6×6.3×-1.7×8.1×-1.9×10×-8.9×
Price / book3.8×-8.3×3.3×-0.7×-0.3×4.3×-5.6×9.9×-1.3×
EV / EBITDA257.4×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Zevra Therapeutics, Inc.'s profit margins?
Zevra Therapeutics, Inc. (ZVRA) runs a 86.1% gross margin and a -103.9% operating margin, with a 101.6% net margin.
Where do Zevra Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Zevra Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.